

Prenatal Care: Anti-D Immune Globulin (NQF 0014)

| | | | |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-------------------------------------------|
| EMeasure Name | Prenatal Care: Anti-D Immune Globulin | EMeasure Id | Pending |
| Version Number | 1 | Set Id | Pending |
| Available Date | No information | Measurement Period | January 1, 20xx through December 31, 20xx |
| Measure Steward | American Medical Association – Physician Consortium for Performance Improvement | | |
| Endorsed By | National Quality Forum | | |
| Description | Percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation. | | |
| Measure scoring | Proportion | | |
| Measure type | Process | | |
| Rationale | <p>Rh sensitization is a serious complication of pregnancy that places the lives of both mother and child at risk. This complication can be avoided through the prophylactic administration of anti-D immune globulin.</p> <p>Antibody tests can be repeated in an unsensitized, D-negative patient at 26-28 weeks gestation. She should also receive anti-D immune globulin prophylactically at that time. In addition, any unsensitized, D-negative patient should receive anti-D immune globulin if she has one of the following conditions or procedures:</p> <ul style="list-style-type: none"> • Ectopic gestation • Abortion (either threatened, spontaneous, or induced) • Procedure associated with possible fetal-to-maternal bleeding, such as chorionic villus sampling (CVS) or amniocentesis • Condition associated with fetal-maternal hemorrhage (eg, abdominal trauma, abruptio placentae) • Delivery of a D-positive newborn (AAP/ACOG) (Level A) <p>The USPSTF recommends the repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks gestation, unless the biological father is known to be Rh (D)-negative. (USPSTF) (B Recommendation).</p> | | |
| Clinical Recommendation Statement | <p>Antibody tests can be repeated in an unsensitized, D-negative patient at 26-28 weeks gestation. She should also receive anti-D immune globulin prophylactically at that time. In addition, any unsensitized, D-negative patient should receive anti-D immune globulin if she has one of the following conditions or procedures:</p> <ul style="list-style-type: none"> • Ectopic gestation • Abortion (either threatened, spontaneous, or induced) • Procedure associated with possible fetal-to-maternal bleeding, such as chorionic villus sampling (CVS) or amniocentesis • Condition associated with fetal-maternal hemorrhage (eg, abdominal trauma, abruptio placentae) • Delivery of a D-positive newborn (AAP/ACOG) (Level A) | | |

| | |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | The USPSTF recommends the repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks gestation, unless the biological father is known to be Rh (D)-negative (USPSTF) (B Recommendation). |
| References | |
| Definitions | |

Table of Contents

- [Population criteria](#)
- [Data criteria \(QDS Data Elements\)](#)
- [Summary calculation](#)

Please refer to the spreadsheet for this measure for detail regarding data criteria and code lists.

Population criteria

- **Initial Patient Population =**
 - AND: "Diagnosis active: delivery live births-diagnosis";
 - AND: "Procedure performed: delivery live births-procedure";
- **Denominator =**
 - AND: "All patients in the initial patient population";
 - AND: "Diagnosis active: D(Rh) negative";
 - OR:
 - AND: "Diagnosis active: primagravida";
 - AND: "Laboratory test result: Rh status mother", value = "negative";
 - OR:
 - AND: "Diagnosis active: multigravida";
 - AND: "Laboratory test result: Rh status mother", value = "negative";
 - AND: "Laboratory test result Rh status baby", value = "negative";
 - AND: "Encounter: prenatal visit"
- **Numerator =**
 - AND "Patient characteristic: estimated date of conception" before or simultaneous to "procedure performed: delivery live births-procedure" <= 10 months
 - AND: "Medication administered: anti-D immune globulin" - "Patient characteristic: estimated date of conception" >= 26 weeks;
 - AND: "Medication administered: anti-D immune globulin" - "Patient characteristic: estimated date of conception" <= 30 weeks;

- **Exclusions =**
 - OR:
 - AND:
 - OR: "Medication administered not done: Patient reason" for "Anti-D Immune Globulin RxNorm Code List"
 - OR: "Medication administered not done: Medical reason" for "Anti-D Immune Globulin RxNorm Code List"
 - ORJ: "Medication administered not done: System reason" for "Anti-D Immune Globulin RxNorm Code List"
 - OR: "Medication administered not done: Anti-D Immune Globulin Declined" for "Anti-D Immune Globulin RxNorm Code List"
 - >= 26 weeks starts after start of ("Patient characteristic: Estimated date of conception" <= 10 month starts before or during ("Procedure performed: Delivery Live Births-Procedure" during "Measurement period"))
 - AND:
 - OR: "Medication administered not done: Patient reason" for "Anti-D Immune Globulin RxNorm Code List"
 - OR: "Medication administered not done: Medical reason" for "Anti-D Immune Globulin RxNorm Code List"
 - OR: "Medication administered not done: System reason" for "Anti-D Immune Globulin RxNorm Code List"
 - OR: "Medication administered not done: Anti-D Immune Globulin Declined" for "Anti-D Immune Globulin RxNorm Code List"
 - <= 30 weeks starts after start of ("Patient characteristic: Estimated date of conception" <= 10 month starts before or during ("Procedure performed: Delivery Live Births-Procedure" during "Measurement period"))

Data criteria (QDS Data Elements)

- **Initial Patient Population =**
 - "Diagnosis active: delivery live births-diagnosis" using the "delivery live births-diagnosis code list grouping" during the "measurement period";
 - "Procedure performed: delivery live births-procedure" using the "delivery live births-procedure code list grouping" during the "measurement period";
- **Denominator =**
 - All patients in the initial patient population;
 - "Diagnosis active: D(Rh) Negative" using the "D(Rh) negative code list" before or simultaneously to the "measurement period";
 - "Diagnosis active: primagravida" using the "primagravida code list" during the "measurement period";
 - "Laboratory test result: Rh status mother" using the "encounter Rh status mother code list" before or simultaneously to "Procedure performed: delivery live births-procedure";

- “Laboratory test result: Rh status baby” using the “encounter Rh status baby code list” before or simultaneously to “Procedure performed: delivery live births-procedure”;
- “Diagnosis: multigravida” using the “multigravida code list” during the “measurement period”;
- “Encounter: prenatal visit” using the “prenatal visit code list” after “Patient characteristic: estimated date of conception”;
- **Numerator =**
 - “Patient characteristic: estimated date of conception” using the “estimated date of conception code list” before “Procedure performed: delivery live births-procedure”;
 - “Medication administered: anti-D immune globulin” using the “anti-D immune globulin code list grouping”;
- **Exclusions =**
 - “Medication not done: patient reason” using the “patient reason code list” for “anti-D immune globulin”;
 - “Medication not done: medical reason” using the “medical reason code list” for “anti-D immune globulin”;
 - “Medication not done: system reason” using the “system reason code list” for “anti-D immune globulin”;
 - “Medication not done: anti-D immune globulin declined” using the “anti-D immune globulin declined code list” for “Medication administered: anti-D immune globulin”;

Summary Calculation

Calculation is generic to all measures:

- Calculate the final denominator by adding all that meet denominator criteria.
- Subtract from the final denominator all that do not meet numerator criteria yet also meet exclusion criteria. Note some measures do not have exclusion criteria.
- The performance calculation is the number meeting numerator criteria divided by the final denominator.
- For measures with multiple patient populations, repeat this process for each patient population and report each result separately.
- For measures with multiple numerators, calculate each numerator separately within each population using the paired exclusion.

| | |
|--------------------|----------------------------------------|
| Measure set | CLINICAL QUALITY MEASURE SET 2011-2012 |
|--------------------|----------------------------------------|